Sarepta Therapeutics Performance degli utili passati
Criteri Il passato verificati 0/6
Sarepta Therapeutics ha registrato una crescita degli utili a un tasso medio annuo di 21.8%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 30%. I ricavi sono stati in crescita a un tasso medio annuo di 31.2%.
Informazioni chiave
21.81%
Tasso di crescita degli utili
25.72%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.04% |
| Tasso di crescita dei ricavi | 31.15% |
| Rendimento del capitale proprio | -62.55% |
| Margine netto | -32.45% |
| Prossimo aggiornamento sugli utili | 06 May 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential
Sarepta Therapeutics' updated analyst price target has shifted modestly, reflecting a lower fair value estimate of $37.42 and a reduced future P/E assumption as analysts weigh mixed siRNA data, updated 2026 revenue guidance, and varying views on Elevidys and the PMO franchise. Analyst Commentary Recent Street research on Sarepta shows a wide range of views, but several bullish analysts are leaning into updated company guidance and new clinical datapoints when revisiting their models.
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Analysts have lifted the blended price target for Sarepta Therapeutics by about $1 to $2, reflecting recent target revisions that balance cautious views on Elevidys revenue guidance and siRNA data quality with more constructive perspectives on early DM1 results and updated 2026 sales and expense models. Analyst Commentary Recent research paints a mixed picture for Sarepta, with analysts updating models around Elevidys, siRNA programs, and early DM1 data.Sarepta Therapeutics: A $2B Business Priced Like It's Broken
Mar 24SRPT: Future Upside Will Hinge On 2026 Gene Therapy Launch Reset
Analysts made a modest upward adjustment to Sarepta Therapeutics' fair value estimate, reflecting updated models around Elevidys launch pacing, 2026 revenue guidance, and revised expectations for profitability and future P/E multiples following recent Q4 results and regulatory commentary. Analyst Commentary Street research on Sarepta around the Q4 update and 2026 guidance reflects a wide range of views on execution risk, Elevidys launch pacing, and the durability of the exon-skipping and gene therapy portfolio.SRPT: Future Upside Will Depend On 2026 Gene Therapy Execution
The analyst price target for Sarepta Therapeutics has moved slightly lower to align with revised 2026 revenue expectations and product launch assumptions, with recent Street targets stepping down in a range from about $45 to $8 as analysts recalibrate Elevidys and other franchise contributions. Analyst Commentary Street views on Sarepta are split, with several firms cutting price targets after management issued 2026 revenue guidance that appears lower than earlier assumptions, while others still see room for execution on the Elevidys and exon-skipping franchises to support value over time.SRPT: Future Risk Reward Will Hinge On Elevidys Execution And Patent Overhang
The analyst price target for Sarepta Therapeutics has been raised by about $0.80. Analysts point to slightly higher fair value estimates, a modestly firmer long term profit margin outlook and updated P/E assumptions, even as they factor in a slightly higher discount rate and restrained revenue expectations.SRPT: Upcoming 2026 Clinical And Regulatory Milestones Will Drive Future Upside
Analysts have edged their price targets on Sarepta Therapeutics higher, with a modest fair value increase of about $0.20 per share. Slightly stronger long run profit expectations more than offset softer modeled revenue growth and a small trim to the assumed future P/E multiple.SRPT: Gene Therapy Catalysts And Access Updates Will Drive Future Upside
Analysts nudged their price target on Sarepta Therapeutics slightly higher, lifting fair value by about US$0.33 to US$39.90 as they factor in updated expectations for Elevidys sales, profitability, and a modestly higher discount rate. Analyst Commentary Recent research on Sarepta highlights a split view on Elevidys, with some pointing to softer near term sales and others focusing on what they see as growing adoption and a broader pipeline story.SRPT: Elevidys Adoption And Pipeline Progress Will Drive Future Upside
Analysts have reset their fair value estimate for Sarepta Therapeutics from US$55.90 to US$39.56. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple following recent research that highlights both improved confidence in Elevidys adoption and ongoing caution from some covering firms.SRPT: Future Risk Reward Will Hinge On Evolving Safety And Coverage Decisions
The analyst price target for Sarepta Therapeutics has been raised slightly, by about $0.20 per share. Analysts attribute this to stronger than expected Elevidys adoption, supportive payer coverage, and a more favorable risk and reward profile, despite unchanged long-term growth and margin assumptions.SRPT: Safety Reviews And Payer Decisions Will Shape Future Risk Reward Balance
Sarepta Therapeutics' fair value estimate has been raised modestly to approximately $20.43 from $19.91, as analysts factor in stronger than expected Elevidys adoption and a more favorable risk or reward profile, despite only incremental improvements in revenue growth and discount rate assumptions. Analyst Commentary Street research on Sarepta has turned more constructive at the margin, with multiple models recalibrated around stronger Elevidys uptake and a clearer path to reimbursement.There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise
Dec 04
SRPT: Ongoing Regulatory Reviews And Safety Updates Will Shape Near-Term Prospects
The analyst price target for Sarepta Therapeutics has been modestly reduced from approximately $21.55 to $19.91. Analysts express mixed expectations based on recent shifts in profit margin projections and ongoing evaluations of Elevidys adoption and safety dynamics.SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Sarepta Therapeutics' analyst price target has been revised downward from approximately $22.88 to $21.55 per share. Analysts cite ongoing concerns over Elevidys uptake, modest improvements to revenue outlook, and persistent profit margin pressures.Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry
Oct 18Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ consensus price target has been lowered from $23.96 to $22.88, primarily due to ongoing Elevidys safety concerns, regulatory uncertainty, and negative sentiment over recent management decisions, outweighing the short-term relief from improved liquidity and regulatory clarity. Analyst Commentary Elevidys safety concerns, including recent patient deaths and new serious adverse event reports, have sustained regulatory uncertainty and contributed to ongoing negative sentiment and price target reductions by Bearish analysts.Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ price target remains under pressure due to persistent safety concerns and regulatory uncertainty surrounding Elevidys, limited market scope after clinical setbacks and halted non-ambulatory development, and skepticism about long-term cash generation, resulting in a maintained consensus analyst price target of $23.84. Analyst Commentary Continued safety concerns surrounding Elevidys, particularly following patient deaths and serious adverse events (notably acute liver failure in non-ambulatory patients and new adverse event reports), have caused repeated reductions in revenue forecasts and increased uncertainty about regulatory approval and commercial uptake.We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
May 29The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
May 08Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 20Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Mar 18Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement
Mar 05Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Mar 04These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well
Jan 22Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Jan 16Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Sarepta Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 2,198 | -713 | 492 | 0 |
| 30 Sep 25 | 2,414 | -272 | 527 | 0 |
| 30 Jun 25 | 2,482 | -58 | 564 | 0 |
| 31 Mar 25 | 2,233 | -248 | 564 | 0 |
| 31 Dec 24 | 1,902 | 235 | 558 | 0 |
| 30 Sep 24 | 1,640 | 122 | 526 | 0 |
| 30 Jun 24 | 1,505 | 47 | 518 | 0 |
| 31 Mar 24 | 1,403 | 17 | 498 | 0 |
| 31 Dec 23 | 1,243 | -536 | 482 | 0 |
| 30 Sep 23 | 1,105 | -691 | 471 | 0 |
| 30 Jun 23 | 1,003 | -908 | 455 | 0 |
| 31 Mar 23 | 976 | -1,115 | 490 | 0 |
| 31 Dec 22 | 933 | -703 | 451 | 0 |
| 30 Sep 22 | 876 | -716 | 409 | 0 |
| 30 Jun 22 | 835 | -507 | 365 | 0 |
| 31 Mar 22 | 766 | -357 | 283 | 0 |
| 31 Dec 21 | 702 | -419 | 283 | 0 |
| 30 Sep 21 | 646 | -486 | 291 | 0 |
| 30 Jun 21 | 600 | -634 | 305 | 0 |
| 31 Mar 21 | 573 | -704 | 306 | 0 |
| 31 Dec 20 | 540 | -554 | 318 | 0 |
| 30 Sep 20 | 495 | -601 | 313 | 0 |
| 30 Jun 20 | 450 | -530 | 313 | 0 |
| 31 Mar 20 | 407 | -656 | 307 | 0 |
| 31 Dec 19 | 381 | -715 | 285 | 0 |
| 30 Sep 19 | 365 | -620 | 268 | 0 |
| 30 Jun 19 | 345 | -570 | 245 | 0 |
| 31 Mar 19 | 323 | -403 | 227 | 0 |
| 31 Dec 18 | 301 | -362 | 208 | 0 |
| 30 Sep 18 | 274 | -245 | 178 | 0 |
| 30 Jun 18 | 241 | -216 | 153 | 0 |
| 31 Mar 18 | 203 | -170 | 133 | 0 |
| 31 Dec 17 | 155 | -51 | 123 | 166 |
| 30 Sep 17 | 103 | -115 | 105 | 0 |
| 30 Jun 17 | 57 | -124 | 99 | 0 |
| 31 Mar 17 | 22 | -123 | 87 | 0 |
| 31 Dec 16 | 5 | -267 | 81 | 0 |
| 30 Sep 16 | 1 | -243 | 85 | 0 |
| 30 Jun 16 | 1 | -239 | 78 | 0 |
| 31 Mar 16 | 1 | -218 | 73 | 0 |
| 31 Dec 15 | 1 | -220 | 66 | 0 |
| 30 Sep 15 | 0 | -200 | 55 | 0 |
| 30 Jun 15 | 1 | -177 | 53 | 0 |
Guadagni di qualità: SRPT al momento non è redditizia.
Margine di profitto in crescita: SRPT al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: SRPT non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 21.8% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di SRPT nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: SRPT non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 40.2% ).
Rendimento del capitale proprio
ROE elevato: SRPT ha un Return on Equity negativo ( -62.55% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/01 13:56 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sarepta Therapeutics, Inc. è coperta da 49 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |